Friday, 13 November 2026
AI scribe use nears half, DVA fee and access reforms, Risk-based PSA screening expands
- 01
AI scribe use reaches 49% in general practice poll
AI scribe use among newsGP readers rose to 49% in a recent poll of 1114 respondents, up from 40% in 2025 and 22% in 2024. RACGP President Dr Michael Wright said the result showed growing comfort with the tools, although continued caution meant adoption remained below half. A Therapeutic Goods Administration review found eight of 12 sampled products were likely to meet the threshold for a medical device, while none of the products considered was listed as one on the Australian Register of Therapeutic Goods. The TGA said many digital scribes now offer generative AI functions beyond transcription and summarisation that may influence diagnosis, monitoring, prognosis or treatment. Dr Wright said potential benefits included more time interacting with patients, but concerns remained about effects on consultation skills and decision-making.
via RACGP newsGP
- 02
Senate committee urges annual DVA fee reviews and access reforms
A Senate committee has called for annual reviews of DVA provider fee schedules and additional measures to improve access to treatment in regional, rural and remote Australia. It said DVA allied health rates had historically been well below sustainable levels, contributing to declining support for veterans, while the Medicare freeze had made low DVA rates difficult for GPs and other specialists to accept. Following the government’s abandonment of a proposed $5000 annual cap on DVA-funded allied health services, the committee recommended legislative protections against arbitrary monetary and numerical restrictions that override clinical need. It also proposed reducing the administrative burden of compensation claims and considering maximum timeframes for decisions.
- 03
US prostate cancer guideline expands risk-based PSA screening
The American Cancer Society now recommends PSA testing every two years from age 50 for men at average prostate cancer risk. It recommends annual testing from age 45 for high-risk groups, including Black men and those with a significant family history of prostate cancer. The guideline authors hope increased surveillance will reduce advanced-stage presentations among Black patients, who are disproportionately represented in prostate cancer mortality. The update reflects recent findings that PSA screening reduced disease-specific mortality for certain men, after the test had fallen out of favour because of its limited specificity.
- 04
Australian program finds one-third of suspected peanut allergies unconfirmed
Supervised oral challenges found that 34.8% of infants suspected of peanut allergy tolerated peanut despite a previous reaction and positive sensitisation testing. Of 778 infants assessed through Australia’s ADAPT program, 271 had no allergic reaction and could have the allergy diagnosis removed. The threshold challenges also established reaction levels to guide starting doses for oral immunotherapy in most infants with confirmed allergy. The researchers said supervised oral food challenges should be routinely considered before infants start immunotherapy because clinical history and sensitisation tests alone did not accurately diagnose many cases.
- 05
Antibiotic-resistant bacteraemia cases continued rising in England in 2025
Antibiotic-resistant bacteraemia cases in England rose to 21,129 in 2025, national surveillance data showed. The UK Health Security Agency recorded an average of 406 cases each week, with the annual total up 16.8% from 18,086 in 2019. The year-on-year increase slowed to 3.2% in 2025, compared with a 9.3% rise between 2023 and 2024. Total NHS antibiotic use fell by 10.7% between 2019 and 2025 amid efforts to promote best prescribing practices and responsible use.
via BMJ
- 06
RACGP opens extended skills recognition pathway for diabetes
RACGP Fellows can now apply for Recognition of Extended Skills in diabetes, formally acknowledging advanced expertise in diabetes prevention, diagnosis and management. Eligibility requires at least five years of RACGP Fellowship and extensive experience across all forms of diabetes, alongside current evidence-based knowledge and contributions beyond individual consultations. Successful participants can display an RACGP Extended Skills sign on their website to help patients identify GPs with this special interest. The RACGP added diabetes in recognition of general practice’s role in managing a fast-growing chronic disease that affects about 5% of Australians, with Aboriginal and Torres Strait Islander peoples almost four times more likely than non-Indigenous Australians to have type 2 diabetes.
via RACGP newsGP
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.